drugset
drugset / Trial / NCT02405858

A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy

NCT02405858 ↗

Phase 4 Completed 51 enrolled Janssen Pharmaceutical K.K.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the percentage of participants achieving prostate-specific antigen (PSA) response by 12 weeks of therapy from baseline according to Prostate Cancer Clinical Trials Working Group (PCWG2) criteria.

Timeline

Start
2015-04-10
Primary completion
2017-12-31
Completion
2017-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Abiraterone acetate Small molecule 1000 mg Oral
Background Prednisolone Other / unclassified 5 mg Oral

Indications

castration-resistant prostate carcinoma